HC 4955
Alternative Names: HC-4955Latest Information Update: 03 Jul 2024
Price :
$50 *
At a glance
- Originator Hinova pharmaceuticals
- Class Antineoplastics; Proteins
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 05 Apr 2024 Preclinical trials in Prostate cancer in China (unspecified route) prior to April 2024
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Prostate cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Hinova pharmaceuticals plans to initiate a clinical trial for Prostate cancer (Metastatic disease, Hormone refractory)